New real-world data showed Trulicity (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment.1 New real-world data showed Trulicity (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment.1 Eli Lilly and Company (NYSE: LLY) presented these data today during the American Diabetes Association's (ADA) 80th Scientific Sessions
Outcomes covered biologic/surrogate (e.g., proteinuria, estimated glomerular filtration rate [eGFR] slope) and hard endpoints (kidney failure, major cardiovascular events, fractures, mortality)
Retatrutide for the treatment of obesity, obstructive sleep apnea and related conditions: TRIUMPH programme
(See Adverse effects .) Adverse effects Potential adverse effects of semaglutide and their underlying mechanisms include the following: Acute kidney injury The exact mechanism for this adverse effect is unknown
At TruTan, our kits are made for both people who are new to this and those who have done it before
The medical team schedules frequent follow-ups during this adjustment period